Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-05-03

Clinical Trial Update: Study of ITCA 650 (Exenatide in DUROS) in Subjects With Type 2 Diabetes Mellitus [Phase 2]

View source ↗

Summary

Phase 2 study of ITCA 650 (exenatide in the DUROS delivery system) for type 2 diabetes mellitus completed with results posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • EXENATIDE (EXENATIDE)
  • ITCA 650

Snippet

Sponsor: Intarcia Therapeutics | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED | Results posted: 2012-05-03